The GORE® VIAFORT Vascular Stent IVC Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2030

Conditions
Venous ThrombosesVenous DiseaseVenous Leg UlcerVenous StasisVenous UlcerVenous StenosisVenous OcclusionVein ThrombosisVein OcclusionVein Disease
Interventions
DEVICE

GORE® VIAFORT Vascular Stent

Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.

Trial Locations (17)

5042

Flinders Medical Centre, Adelaide

10029

Mount Sinai Medical Center, New York

10065

Weill Cornell Medical College, New York

20010

MedStar Washington Hospital Center, Washington D.C.

20132

Ospedale San Raffaele, Milan

23507

Sentara, Norfolk

28204

Atrium Health-Sanger Heart and Vascular Institute, Charlotte

41125

Hesperia Hospital, Modena

48109

University of Michigan, Ann Arbor

52074

Universitätsklinikum Aachen, Aachen

59759

Alexianer Klinikum Hochsauerland GmbH, Arnsberg

60611

Northwestern, Chicago

94305

Stanford University School of Medicine, Stanford

H91 YR71

University College Hospital GALWAY /Clinical Research Facility Galway, Galway

Unknown

Auckland City Hospital, Auckland

CB2 0QQ

Addenbrooke's Hospital, Cambridge

SE1 7EH

St Thomas' Hospital, London

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY